The Chan Zuckerberg Initiative has announced a $25 million commitment in support of the COVID-19 Therapeutics Accelerator, a global initiative aimed at accelerating the development of treatments for the disease caused by the novel coronavirus.
Launched earlier this month with $125 million in commitments from the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, the accelerator supports efforts to expedite and evaluate new and repurposed drugs for COVID-19. The initiative also will work to ensure equal access to the therapies once they are developed — including making them available and affordable in underserved communities. To that end, CZI is providing $20 million in support of the accelerator, with another $5 million available for future needs.
"In joining the COVID-19 Therapeutics Accelerator, we're taking part in a coordinated response that will help address this outbreak, and future outbreaks as well," said CZI's head of science, Cori Bargmann. "By working together, we can dramatically accelerate drug development and deployment to find the effective therapeutics that will ultimately save lives."
"We're excited to partner with the Gates Foundation, Wellcome, and Mastercard to help the biomedical research community quickly identify, develop, and test treatments for COVID-19," said CZI co-founders and co-CEOs Priscilla Chan and Mark Zuckerberg. "The Therapeutics Accelerator will enable researchers to quickly determine whether or not existing drugs have a potential benefit against COVID-19. We hope these coordinated efforts will help stop the spread of COVID-19 as well as provide shared, reusable strategies to respond to future pandemics."
(Photo credit: Dieter Telemans/Panos Pictures)